Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 291 participants.
Also called NCT01135225
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 291 participants
- Sponsor
- Registry
-
NCT01135225
-
- Other papers using this trial's data
- Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent
- Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Belgium, Denmark, France, New Zealand, Poland, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01135225. Randomized; single masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2011-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent
- Acronym
- Evolve
- Condition
- Coronary Artery Disease
- Intervention (Device)
- PROMUS(TM) Element (TM) Stent System
- Intervention (Device)
- Evolution Stent System
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct01135225- Content hash
242a5c721615f7cce1d687d4ba0eb93914a1dbe5c1a50027bb96fc986ae28b0e